Article

Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin

Asian Liver Center, Department of Surgery, 1201 Welch Road, Stanford University School of Medicine, Stanford, CA 94305, USA.
Molecular Cancer (Impact Factor: 5.4). 02/2011; 10:16. DOI: 10.1186/1476-4598-10-16
Source: PubMed

ABSTRACT There are limited therapeutic options for hepatocellular carcinoma (HCC), the most common liver malignancy worldwide. Recent studies have identified the Frizzled-7 receptor (FZD7), important for activation of Wnt-mediated signaling, as a potential therapeutic target for HCC and other cancers.
We hypothesized that the extracellular domain of FZD7 (sFZD7) would be a clinically more relevant therapeutic modality than previously studied approaches to target FZD7. We expressed and purified sFZD7 from E. coli, and tested its functional activity to interact with Wnt3, its ability to inhibit Wnt3-mediated signaling, and its potential for combinatorial therapy in HCC.
sFZD7 pulled down Wnt3 from Huh7 cells, and decreased β-catenin/Tcf4 transcriptional activity in HCC cells. In vitro, sFZD7 dose-dependently decreased viability of three HCC cell lines (HepG2, Hep40, and Huh7, all with high FZD7 and Wnt3 mRNA), but had little effect on normal hepatocytes from three donors (all with low level FZD7 and Wnt3 mRNA). When combined with doxorubicin, sFZD7 enhanced the growth inhibitory effects of doxorubicin against HCC cells in vitro, and against Huh7 xenografts in vivo. Reduced expressions of c-Myc, cyclin D1, and survivin were observed in vitro and in vivo. Additionally, sFZD7 altered the levels of phosphorylated AKT and ERK1/2 induced by doxorubicin treatment in vitro, suggesting that several critical pathways are involved in the chemosensitizing effect of sFZD7.
We propose that sFZD7 is a feasible therapeutic agent with specific activity, which can potentially be combined with other chemotherapeutic agents for the improved management of HCC.

Full-text

Available from: Mei-Sze Chua, Jan 07, 2014
0 Followers
 · 
150 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A specific targeting modality for hepatocellular carcinoma (HCC) could ideally encompass a liver cell specific delivery system of a transcriptional unit that is active only in neoplastic cells. Sendai virosomes, derived from Sendai viral envelopes, home to hepatocytes based on the liver specific expression of asialoglycoprotein receptors (ASGPRs) which are recognized by the Sendai virosomal fusion (F) proteins. As reported earlier by us and other groups, transcriptional gene silencing (TGS) does not require continuous presence of the effector siRNA/shRNA molecule and is heritable, involving epigenetic modifications, leading to long term transcriptional repression. This could be advantageous over conventional gene therapy approaches, since continuous c-Myc inactivation is required to suppress hepatocarcinoma cells.
    BMC Cancer 08/2014; 14(1):582. DOI:10.1186/1471-2407-14-582 · 3.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT S-adenosylmethionine (SAMe), the principal methyl donor that is available as a nutritional supplement, and its metabolite methylthioadenosine (MTA) exert chemopreventive properties against liver and colon cancer in experimental models. Both agents reduced beta catenin expression on immunohistochemistry in a murine colitis-associated colon cancer (CAC) model. Here we examined the molecular mechanisms involved. SAMe or MTA treatment in the CAC model lowered total beta catenin protein levels by 47 and 78%, respectively. In an orthotopic liver cancer model, increasing SAMe levels by overexpressing methionine adenosyltransferase 1A also reduced total beta catenin levels by 68%. In both cases, lower cyclin D1 and c-Myc expression correlated with lower beta catenin levels. In liver (HepG2) and colon (SW480, HCT116) cancer cells with constitutively active beta catenin signaling, SAMe and MTA treatment inhibited beta catenin activity by excluding it from the nuclear compartment. However, in liver (Huh-7) and colon (RKO) cancer cells expressing wild type Wnt/beta catenin, SAMe and MTA accelerated beta catenin degradation by a GSK-β-dependent mechanism. Both agents lowered AKT activity but this was not mediated by inhibiting phosphoinositide 3-kinase. Instead, both agents increased the activity of protein phosphatase 2A, which inactivates AKT. The effect of MTA on lowering beta catenin is direct and not mediated by its conversion to SAMe as blocking this conversion had no influence. In conclusion, SAMe and MTA inhibit Wnt/beta catenin signaling in colon and liver cancer cells regardless of whether this pathway is aberrantly induced, making them ideal candidates for chemoprevention and/or chemotherapy in these cancers.
    Molecular pharmacology 10/2014; 87(1). DOI:10.1124/mol.114.095679 · 4.12 Impact Factor
  • Source
    Gastroenterology 05/2014; 146(5):S-813. DOI:10.1016/S0016-5085(14)62940-1 · 13.93 Impact Factor